BOTTOM PLAYS! CHART TECH! RESEARCH! STRATEGIES!

[mattsinvestmentclub]

$OMHE 34+ PAGE DUE DILIGENCE BOTTOM PLAY TRIPLE 0'S

34+ PAGE DUE DILIGENCE PACKET

L2:




CURRENT ISSUES WITH COMPANY:
NVSOS=DELINQUENT
DELEWARE SUBS DELINQUENT "ENTOURAGE BIOTECH, AGELOCK BIOTECH, CELEBRITY BRANDS LLC, LX RETAIL GROUP INC".
pending suit for violation of promissory note "due to form 15 filing"

STILL WORTH A WATCH-LIST RECOMMENDATION MINIMUM.

[exec_sum]

$TRBO Priced at 7 cents its a no brainer was at $2.70

[Golden Cross]

$GBHL Bottom Chart Play - Nice volume last few days.

Bullish Chart
https://www.barchart.com/stocks/quotes/GBHL/technical-chart?plot=BAR&volume=total&data=DO&density=M&pricesOn=1&asPctChange=0&logscale=0&indicators=SMA(10);SMA(50);SMA(200);RSI(14,100);ACCUM;MFI(14,100);SMACD(12,26,9)&sym=GBHL&grid=1&height=500&studyheight=100

[JohnCM]

UATG

Volume 7,393,000

Up $0.0002 $0.0019

[Shavasana]

$WRFX. Bottom

[MaxPowerLove$Ihub]

$ZNGY: could run like TT** (II), MG*

[JohnCM]

JETMF

[JohnCM]

[MaxPowerLove$Ihub]

$EMLL: $.0001s play

[exec_sum]

$SMPI - Trading Green On Breaking News Keep Watch

[JohnCM]

Is this the best place to put your money?



I say go with USLV.

[exec_sum]

$SMPI - Bottom Bounce Play Looking Solid

[JohnCM]

Trivago N.V. ADS (TRVG)
6.84 0.37 (5.72%)

[JohnCM]

Downside risk is almost nil.

[JohnCM]

My BOTTOM PLAYS did not pan out.

I will switch my strategy.

CDE still holding
UAA out
TRVG out
AMD still holding
VRX piled in

[JohnCM]

Valeant: Vyzulta Approval Actually Big News

Nov. 7, 2017 12:23 PM ET Seeking Alpha

FDA approved the NDA for Vyzulta after Valeant cleared the necessary hurdles.

A quick look at the market opportunity for the drug.

It's hard to criticize Valeant's pipeline when it continues to produce new commercial products and advances in other notable candidates.

Can new revenue streams make a meaningful difference for Valeant's earnings?

Valeant Pharmaceuticals International Inc. (VRX) got its long awaited approval for Vyzulta after working out the issues affecting its Tampa, Fla., manufacturing facility. Valeant expects to get Vyzulta on the market as quickly as possible with a good chance at grabbing some key market share in 2018, as there is a sizable opportunity for the drug given its advantages over competition. Criticizing Valeant's pipeline of drugs gets harder and harder for bears to do when the company continues to successfully bring new products to commercial viability while advancing early stage candidates at a rapid pace.

The FDA approved the New Drug Application for Vyzulta (latanoprostene bunod ophthalmic solution, 0.024%) as the first prostaglandin analog with one of its metabolites being nitric oxide. It is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. This is fine and dandy, but what I always want to know is what sets it apart from the competition and can it grab market share in the coming years. Vyzulta is a molecule with a dual mechanism of action that creates significant, consistent and sustained (IOP) reduction over a 12-month period. It has shown multiple statistically significant results in IOP lowering and efficacy compared to other glaucoma drugs and will look to grab market share from key glaucoma players in the space including Pfizer (PFE), Novartis (NVS), and Allergan (AGN).

The drug approval has been on hold since August when Valeant got a Complete Response Letter from the FDA citing Current Good Manufacturing Practice (CGMP) issues with the company's manufacturing facility in Tampa, Fl. These issues got cleared up when Valeant got a Voluntary Action Indicated (VAI) inspection classification later in August mentioning that the facility still had concerns, but that those concerns were below the threshold of regulatory significance. With all the regulatory issues cleared up, Valeant CEO Joseph Papa was confident enough to state that "We expect to make this new advancement available for those who suffer with glaucoma before the end of the year."

Now, what does the market look like for Vyzulta in 2018 when it attempts to seize market share from its competition? According to Valeant, the company estimates approximately 3 million people in the U.S. suffer from glaucoma with a total glaucoma market opportunity at close to $3 billion. Prostaglandin-analog class drugs, such as Vyzulta, account for roughly $1.6 billion of the total market with about 17 million prescriptions written annually.

Having a superior product, in many respects, to a lot of the competition entering a $1.6 billion dollar market is a big deal. This is just one of Valeant's new products that looks to make a significant impact on sales growth in the coming years with the possibility that Siliq also might make a meaningful impact on dermatology sales. Other pipeline progressions also continue including the latest FDA acceptance of Valeant's marketing application for IDP-118 (halobetasol propionate and tazarotene) lotion for the topical treatment of plaque psoriasis with a June 18, 2018, action date.

Finally, will new commercial products like Vyzulta and Siliq move the needle for Valeant as they both look to seize share in billion-dollar market niches? The company is focused on paying down debt by selling non-core assets and growing revenues as it continues its turnaround strategy so new meaningful revenue streams would be crucial. Here are some revenue and EBITDA numbers over the last year along with the revenue numbers for Dermatology (Siliq) and the company's Bausch + Lomb/International (Vyzulta) segments.

Valeant Revenues Adj. EBITDA Dermatology B + L
Q2, 2017 2.23B 951M 130M 1.24B
Q1, 2017 2.11B 861M 192M 1.15B
Q4, 2016 2.40B 1.05B 214M 1.18B
Q3, 2016 2.48B 1.16B 223M 1.16B
Q2, 2016 2.42B 1.09B 188M 1.28B

As Valeant focuses on aggressively paying down its debt load, growing revenues with new products like Vyzulta will have a chance to produce meaningful new revenue streams that will potentially make a difference, not only in their respective segments but on the company's earnings as a whole. I look for Vyzulta in particular to start making a big splash especially in the second half of 2018. If Valeant can show some consistent growth and momentum next year with new growing revenue streams, look for market sentiment to finally start to shift positive as the company's debt burden continues to shrink. Best of luck to all.

[JohnCM]

Under Armour to make MLB uniforms in 2019, a year early

May 19, 2017 ESPN.com news services

NEW YORK -- Under Armour and Fanatics will take over for Majestic and Nike as the official uniform partners for Major League Baseball in 2019, a year earlier than previously scheduled.

Under Armour, Fanatics' uniform deal announced

The on-field deal between MLB, Under Armour and Fanatics is scheduled to begin in 2020 and run for 10 years, but sources say it could start before that should Majestic decide to bow out early.

Under the terms of the deal, Under Armour will make all on-field apparel, including jerseys and game-day and training outerwear, that is currently made by Majestic, and base-layer gear that is made by Nike.

Fanatics, the largest sports retailer, will make the merchandise that will be sold to fans, serving as both the producer and the seller.

Fanatics Inc. and MLB announced an agreement in December that gave the company licensing rights to manufacture and distribute merchandise starting in 2020. Fanatics signed a deal last month to buy VF Corp.'s Licensed Sports Group and with it the 600-worker Majestic Athletic plant in Easton, Pennsylvania, where team jerseys and fan apparel are manufactured.

Baseball Commissioner Rob Manfred said Thursday that fan merchandise from Under Armour will be available next year and that Under Armour will be worn for dugout clothing during the 2018 postseason. The full switch to Under Armour for on-field apparel will take place for the 2019 season.

Majestic has manufactured MLB batting practice jerseys since 1982 and has been the exclusive supplier of game uniforms since 2005. Before that, uniforms were manufactured by both Majestic and Russell.

[JohnCM]

[JohnCM]

BUY with stop loss at $3.99

RSI(14) 8.58 That must be a record.

This report looks good. Not sure about margins. Do not follow this company.

GenMark Diagnostics Reports Third Quarter 2017 Results

Genmark Diagnostics, Inc. (MM) (NASDAQ:GNMK)

Saturday 4 November 2017

GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the third quarter ended September 30, 2017.

Third Quarter Highlights

Placed 65 ePlex® analyzers in the third quarter, mostly driven by first full quarter of U.S. launch

Finished the quarter with an installed base of 147 ePlex analyzers in U.S. and European labs

Achieved revenues of $11.6 million in the quarter, an increase of 7.3% over the prior year period

“We are pleased with our first full quarter of ePlex launch in the U.S., which drove the majority of placements in the third quarter,” said Hany Massarany, President and Chief Executive Officer. “With strong sales funnels and continued positive customer feedback regarding the overall performance of ePlex, we remain optimistic about our opportunity to accelerate our revenue growth rate and capture market share in the global multiplex molecular diagnostics market.”

Third Quarter Financial Results

Revenue was $11.6 million in the third quarter of 2017, an increase of 7.3% versus $10.7 million in the third quarter of 2016. Gross profit was $4.2 million, or 36% of revenue, compared with $6.5 million, or 60% of revenue in the same period of 2016.

Operating expenses for the third quarter of 2017 were $18.9 million compared to $18.1 million in the same period for 2016. The increase was mainly driven by sales and marketing expenses as the Company continues to expand its commercial organization in support of the global ePlex product launch.

Loss per share was $0.28 per share for the third quarter of 2017, compared to a $0.27 loss per share in the third quarter of 2016.

The Company ended the quarter with $86.9 million in cash and investments.

Business Outlook

For full year 2017, GenMark expects revenue to range from $51 - $53 million and gross margin to range from 38% to 40%. The Company expects to exit 2017 with 185-200 ePlex placements.

[JohnCM]

AMD turned out good.

[JohnCM]

UAA

[JohnCM]

short?

https://www.msn.com/en-us/money/companies/sears-depletes-dollar200-million-loan-in-latest-sign-of-cash-burn/ar-AAufiT3?ocid=spartandhp

[JohnCM]

[JohnCM]

BUY

[JohnCM]

CDE Couer Mining

EGO Eldorado Mining

AMD Advanced Micro Devices

MOMO Momo Chinese Internet

TRVG Trivago Leasure

[MaxPowerLove$Ihub]

$MEDT: $.000x play~ it's endorsed by rappers! POS is deeply undervalued!

[MaxPowerLove$Ihub]

***** $CHRO: ****** $mart MMs/brokerages would load up & go long...Why? This has a PPS of $1.00s+ written all over!!!

Spend 30-60 minutes to read the DDs & watch the related videos & one will see the potential of this stock! Wait & see...Institutional buyers/investors will take this to silver land & then dollar land! *****

Google's Acquisition of Nest Closes the Loop on the Smart Home

Amazon Echo home automation and Wink smart home

The smart home of the future - Amazing futuristic concept

Inside Microsoft's house of the future

Honda Smart Home US Overview

- Go CHRO

[MaxPowerLove$Ihub]

$SURE, $VGID, $GNPT: aiming for $.00x

[MaxPowerLove$Ihub]

$COBI: could be a 10-50x bagga in the long-run

[ConstructionKing]

Apyp

[MaxPowerLove$Ihub]

$CHRO: This is how CHRO Longs (supporters, believers, ask-slappers) beat up un-neuter MM-CSTI~

Poor POS-MM NITE...hurt eh?

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=121438395

- Go CHRO

[MaxPowerLove$Ihub]

$CHRO: $.0389s...& achieving .04s marks our first milestone to the path of $.25s+!


- Go CHRO

[TRAPPER JIM]

NSFC Chart bouncing off the 50 DMA. Those 2 shares that sold today at 0.57 dipped to the 50DMA and closing at 0.59 looks like the uptrend is still in tact Golden Cross still coming up.

[XtraFunds]

Keep an eye out on $GLDG

[MaxPowerLove$Ihub]

$LUSI, $FRGY, $ITCJ: 1s play

[hvernaza25]

$VAPE trying to make a run

[WallStreetMyWay]

As I am convinced that $IDGC as things progresses are going to improve for this particular company in the foreseeable future, an by all means DD and don't take my word for it. But put it on your radar.

We could be presented with something at bottom levels and positioned for a strong reversal.

http://www.otcmarkets.com/stock/IDGC/financials#

[DispatchTrader]

IJJP - good to keep on watch it's hit bottom, has reduced share price last month so no dilution , good financials last quarter, been shorted heavily, so will need to cover, just waiting on update, plus not a lot of debt. :)

[CantMiss26]

IDNG worth a look folks.